Atlas Trials

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT04436107 · COMPLETED

Trial details

NCT number
NCT04436107
Sponsor
BeiGene
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Start date
2020-09-11
Primary completion
2024-03-28
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.